Trials / Recruiting
RecruitingNCT06247839
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Sharmin Ghaznavi · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Psilocybin | COMP360 (Brand name of psilocybin to be used) |
Timeline
- Start date
- 2024-09-10
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2024-02-08
- Last updated
- 2025-05-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06247839. Inclusion in this directory is not an endorsement.